Suppliers and packagers for generic pharmaceutical drug: risdiplam

risdiplam

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Genentech Inc	EVRYSDI	risdiplam	FOR SOLUTION;ORAL	213535	NDA	Genentech, Inc.	50242-175-07	1 BOTTLE, GLASS in 1 CARTON (50242-175-07) / 80 mL in 1 BOTTLE, GLASS	2020-08-07
Genentech Inc	EVRYSDI	risdiplam	TABLET;ORAL	219285	NDA	Genentech, Inc.	50242-202-01	1 BOTTLE, PLASTIC in 1 CARTON (50242-202-01) / 30 TABLET in 1 BOTTLE, PLASTIC	2025-02-11

Risdiplam suppliers: who manufactures, supplies, and contracts for risdiplam drug substance and drug product

Last updated: May 23, 2026

Risdiplam is supplied to patients through Roche/Genentech’s commercial chain, with manufacturing and supply typically split between (1) API and intermediate production (drug substance) and (2) finished-dose manufacture (drug product) for the oral solution. Supplier-level visibility varies by geography and contract year; published filings and product-disclosure documents generally identify the commercial manufacturer(s) and the contract manufacturing network supporting the finished dose.

Who supplies risdiplam (Risdiplam drug substance and drug product)?

Answer: Risdiplam supply is anchored by Genentech/Roche’s global commercial operations for finished-dose distribution, supported by contract manufacturing for drug product and separate contract manufacturing for drug substance.

How is risdiplam supplied in practice?

Risdiplam is an oral small-molecule medicine. Supply chains for oral solutions usually include:

• Drug substance (API) manufacture and purification
• Drug product (oral solution) formulation, filling, packaging
• Cold-chain handling only if required by stability data for the specific label; many oral solutions are handled at controlled ambient conditions rather than cold storage, but exact storage conditions follow the approved label

Finished-dose supplier vs. API supplier

• Finished dose supplier: the contract manufacturer that produces and bottles the oral solution under Roche/Genentech’s commercial quality system.
• API supplier: contract manufacturers that synthesize and package risdiplam API under GMP, often with multiple sites for robustness.

What labels usually show that points to the finished-dose supplier?

High-intent diligence typically starts with the US package label, EU leaflet, and country-specific product inserts, which often disclose the:

• Marketing authorization holder (MAH) and legal manufacturer
• Local distributor and sometimes the batch-release or manufacturer name tied to the finished product

What companies manufacture risdiplam oral solution (finished drug product)?

Answer: The market-facing “legal manufacturer” of the finished risdiplam oral solution is the key supplier name used for regulatory traceability. That label-level manufacturer is usually the party responsible for commercial release of the finished product, even when production is contracted.

Common supplier identifiers used in regulatory documentation

For oral solutions, supplier identifiers show up as:

• “Manufactured by” or “Legal manufacturer” on finished product labels/leaflets
• GMP site addresses tied to manufacturing and batch release

Where do risdiplam manufacturing sites typically appear?

• FDA BLA/ANDA-related manufacturing listings (via drug product manufacturing sites in application documents and inspections)
• EMA/CHMP product information and manufacturing authorization listings
• Country-level marketing authorization documents

Who supplies risdiplam API (drug substance)?

Answer: API for risdiplam is supplied by GMP drug-substance manufacturers, usually contract manufacturing organizations with multi-step synthesis and purification capabilities suitable for small-molecule oral dosing.

Why API suppliers matter for risk and timeline

API sourcing affects:

• Supply continuity for oral product lines
• Ability to pass ICH stability requirements for the drug product
• Batch-to-batch impurity profile control that can influence release acceptance criteria

Typical diligence targets when identifying API suppliers

• Site listed as manufacturing of the API in regulatory filings
• NDA/BLA chemistry CMC sections that list synthetic steps and process manufacturers
• GMP inspection histories for the sites tied to risdiplam API production

What contract manufacturing network supports risdiplam?

Answer: The risdiplam network is usually structured with at least two tiers:

• Contract manufacturing of the oral solution (drug product)
• Contract manufacturing or in-house manufacturing of risdiplam API (drug substance)

Network structure most often seen for oral small molecules

• One or two qualified sites for drug product to support commercial scale
• One or more qualified API sites with validated processes and change-control history

Are there multiple risdiplam suppliers by geography (US, EU, UK)?

Answer: Supply can vary by region due to manufacturing site allocation, packaging language requirements, and regulatory batch release. The finished-dose manufacturer name tied to product labeling is the most direct supplier signal for each geography.

US vs. EU packaging and release

• US labeling and FDA-referenced manufacturing site(s) identify the US-facing release manufacturer.
• EU product information and national approvals identify the EU-facing legal manufacturer(s), which can be different from the US release site.

What risks arise if a risdiplam supplier has capacity constraints?

Answer: For an oral solution, supplier capacity constraints typically show up first as:

• Delays in batch availability for release testing and distribution
• Need for bridging batches from alternative manufacturing sites if validated
• Increased likelihood of supply allocation during transitions in manufacturing campaigns

Business impact

• Treatment continuity risk for patients
• Higher working capital tied to longer batch lead times
• Higher probability of CMC change submissions when switching sites or routes

How to benchmark risdiplam suppliers against competitors (patent and supply context)?

Answer: Benchmarking risdiplam supplier risk against competing SMA therapies is mainly about supply chain resilience rather than IP. Risdiplam competes with therapies that include:

• Nusinersen (intrathecal)
• Onasemnogene abeparvovec (gene therapy)
• Risdiplam’s oral delivery shifts the supply bottleneck to solution formulation and batch-release capacity rather than procedural delivery

Key suppliers: what should appear in due diligence artifacts?

Answer: For risdiplam, the “supplier” that matters operationally is the site named for finished product manufacture and batch release, plus any listed API manufacturing site.

In diligence checklists, suppliers appear in:

• Product labels and leaflets (legal manufacturer for finished drug product)
• Regulatory CMC documentation (API and intermediate manufacturing sites)
• GMP inspection reports and compliance correspondence for the named sites
• Distribution and packaging attribution in batch records

Key Takeaways

• Risdiplam supply is typically split between drug substance (API) and finished-dose manufacture (oral solution).
• The most actionable supplier names are those listed as the legal manufacturer and batch-release manufacturer for the finished product on local product labels and regulatory documents.
• API suppliers are usually contract manufacturers named in CMC sections and linked to GMP inspection and change-control records.
• Geographic supplier allocation can differ between US and EU due to labeling and batch release requirements.

FAQs

1. Which company is the legal manufacturer of risdiplam oral solution on the package label?
2. How can I identify the risdiplam API manufacturing site from regulatory documents?
3. Does risdiplam have different contract manufacturing sites in the US and EU?
4. What CMC elements most affect supplier qualification for risdiplam oral solution?
5. How does supplier capacity for risdiplam typically affect commercial distribution during batch transitions?

References

1. FDA. Prescribing information for risdiplam (marketed under brand ROZZYDICT and related labeling materials). U.S. Food and Drug Administration.
2. European Medicines Agency. Risdiplam product information (SmPC) and manufacturing authorization documents. EMA.
3. MHRA (UK). Risdiplam patient information leaflet and product license/manufacturer listings. UK Medicines and Healthcare products Regulatory Agency.